2020 Fiscal Year Final Research Report
Regulation of oxidative metabolic product-mediated immune suppressive tumor microenvironment to improve the efficacy of immune checkpoint blockade therapy in cancers.
| Project/Area Number |
19K16808
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2021-03-31
|
| Keywords | VAP-1 inhibitor / Immunosuppression / H2O2 / CTLs / ICIs |
|---|
| Outline of Final Research Achievements |
Immunotherapy is a promising treatment modality for cancer. In this study we showed that inhibition of vascular adhesion protein 1, partly responsible for generating immunosuppressive microenvironment, can reverse the unfavorable immune-environment and synergize with current approve immunotherapy.
|
| Free Research Field |
Tumor immunotherapy
|
| Academic Significance and Societal Importance of the Research Achievements |
This study showed that oxidative tumor microenvironment can generate immunosuppressive element. This immunosuppression can be altered by inhibiting a particular adhesion protein. This information may help to revise patient care for immunotherapy.
|
